Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Oncoimmunology|August 21, 2019
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-lineAnna Kreutzman, Bhagwan Yadav, Tim H Brummendorf, et al.
European Journal of Haematology|August 21, 2021
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 studyHjalmar Flygt, Stina Söderlund, Jesper Stentoft, et al.
Blood|July 12, 2013
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registryMartin Höglund, Fredrik Sandin, Karin Hellström, et al.
Experimental Hematology|July 31, 2012
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemiaAnna Kreutzman, Taina Jaatinen, Dario Greco, et al.
European Journal of Haematology|August 2, 2014
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)Henrik Hjorth-Hansen, Leif Stenke, Stina Söderlund, et al.
Leukemia|January 26, 2024
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trialHjalmar Flygt, Stina Söderlund, Johan Richter, et al.
Annals of Hematology|April 29, 2023
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effectsInge G P Geelen, Stein-Erik Gullaksen, Mette M Ilander, et al.
Blood Advances|July 8, 2018
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemiaAnne-Sophie Bouillon, Monica S Ventura Ferreira, Shady Adnan Awad, et al.
Leukemia|July 10, 2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI TrialFabio Efficace, Francois-Xavier Mahon, Johan Richter, et al.
The Journal of Clinical Investigation|September 1, 2022
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemiaJani Huuhtanen, Mette Ilander, Bhagwan Yadav, et al.
Pageof 11